Overview

A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Status:
Not yet recruiting
Trial end date:
2023-10-09
Target enrollment:
Participant gender:
Summary
The goal of this phase 1 study is to assess the pharmacokinetics, safety and tolerability following multiple oral doses of TVB-2640 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Sagimet Biosciences Inc.